Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University Hospital, Daegu, Korea.
Acta Oncol. 2011 Nov;50(8):1228-34. doi: 10.3109/0284186X.2011.602109. Epub 2011 Aug 28.
The relationship between Hashimoto's thyroiditis (HT) and papillary thyroid cancer (PTC) with regard to their co-occurrence and the effect of concurrent HT on the prognosis of PTC has been debated. The aim of the present study is to determine a clinical relationship between these two disease entities and to evaluate the correlation between concurrent HT and various clinicopathological parameters.
Demographic and histopathological data were collected from 675 patients undergoing thyroid surgery from 2000 to 2005, and 303 patients who received initial treatment for thyroid disease at our institution and whose medical records were accessible for review were enrolled in this study. Of these participants, 269 with histologically confirmed PTC were analysed according to the presence or absence of concurrent HT.
Of 269 patients with PTC, 21.6% (58/269) had concurrent HT, whereas only 5.9% (2/34) had concurrent HT with another diagnosis (p = 0.031, odds ratio = 4.4; 95% CI, 1.02-18.90). Younger age at presentation and a greater female preponderance were noted in patients with HT compared with those without HT (p = 0.008 and p = 0.009, respectively). Although it was not statistically significant, PTC with HT patients tented to have smaller tumour size (1.6 ± 1.0 cm vs. 1.8 ± 1.5 cm), lower incidence of lymph node metastasis at presentation (12.2% vs. 29.9%), unifocal disease (84.5% vs. 78.7%), and early-stage disease. Additionally, PTC with HT patients exhibited better prognosis, viewed in recurrence and mortality, during the 62-month mean follow-up period.
HT was definitely associated with PTC as was chronic inflammation with cancer in other locations. Interestingly, however, the coexistence of HT in PTC cases introduced favourable clinical outcomes compared with those of PTC without HT.
桥本甲状腺炎(HT)与甲状腺乳头状癌(PTC)的共存关系及其共存 HT 对 PTC 预后的影响一直存在争议。本研究旨在确定这两种疾病实体之间的临床关系,并评估共存 HT 与各种临床病理参数之间的相关性。
从 2000 年至 2005 年接受甲状腺手术的 675 例患者中收集人口统计学和组织病理学数据,并对在我院接受初始甲状腺疾病治疗且病历可查阅的 303 例患者进行了本项研究。在这些参与者中,根据是否存在共存 HT,对 269 例经组织学证实的 PTC 患者进行了分析。
在 269 例 PTC 患者中,21.6%(58/269)有共存 HT,而仅有 5.9%(2/34)有共存 HT 伴另一种诊断(p = 0.031,优势比= 4.4;95%置信区间,1.02-18.90)。与无 HT 患者相比,HT 患者的发病年龄更小,女性比例更高(p = 0.008 和 p = 0.009)。尽管没有统计学意义,但 HT 合并 PTC 患者的肿瘤直径较小(1.6 ± 1.0 cm 比 1.8 ± 1.5 cm)、发病时淋巴结转移发生率较低(12.2%比 29.9%)、单发肿瘤(84.5%比 78.7%)和早期疾病。此外,在 62 个月的平均随访期间,HT 合并 PTC 患者在复发和死亡率方面表现出更好的预后。
HT 确实与 PTC 相关,正如其他部位的慢性炎症与癌症相关一样。然而,有趣的是,与无 HT 的 PTC 相比,HT 合并 PTC 病例的共存会带来更好的临床结局。